Please ensure Javascript is enabled for purposes of website accessibility
Maxx Chatsko

Maxx Chatsko

XMFBlacknGoldX

Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.

Recent articles

dude tossing stacks

Here's Why Fluidigm Soared as Much as 58.6% Today

The struggling laboratory hardware developer received a $37 million infusion to tackle the coronavirus pandemic.


202 yellow traffic light

Coronavirus Vaccine Stocks: Investors Cannot Overlook These Risks

If coronavirus vaccine development efforts are a race, then pharmaceutical companies will need to hurdle more than clinical trials to be successful.


076 arrow dude getty

Here's Why MediciNova Is Soaring Today

The small-cap pharmaceutical company announced a collaboration to develop a coronavirus vaccine.


arrow up shelves

Here's Why Amyris Stock Rose as Much as 12.2% Today

The synthetic biology pioneer announced a collaboration for its vaccine adjuvant ambitions.


242 hydrogen leaf

Missing in the Hydrogen Economy Pitch: The Tax Credit Cliff for Fuel Cells

Fuel-cell manufacturers have fixed the eyes of investors on the growth potential of a hydrogen economy, but it might be distracting from a looming financial crunch.

034 greedy businessman

Twist Bioscience Has Gained 186% in 2020. Is the Synbio Stock a Buy?

The company's $2.7 billion valuation is being driven by the coronavirus pandemic and federal stimulus. It doesn't appear sustainable.


248 nuclear cooling towers

U.S. Uranium Output Hit an All-Time Low in 2019. Does It Matter?

Nuclear power plants provide roughly 20% of the nation's electricity, but domestic uranium production could have met just 0.4% of fuel requirements last year.


dude pointing up

2 Stocks to Hold for the Next 20 Years

Two decades is a long time, but these up-and-coming biopharma companies could earn significantly larger valuations in that span.


000 businessman celebrate sad

Fuel Cell Investors Shouldn't Get Too Caught Up in the Hydrogen Economy Just Yet

Dreams of a hydrogen future have sent fuel cell stocks soaring in 2020, but investors might get burned by the technological hype.


people re cut outs

Renewable Energy Is the New Growth Driver for Dominion Energy

The unexpected sale of its gas transmission and storage business makes regulated utility operations, and renewable energy, more important than ever.

534 question cards wooden box

Is Neoleukin Therapeutics a Buy?

The drug developer has an intriguing technology platform and expects to enter clinical trials before the end of 2020, but there are a few things investors cannot overlook.


blocks arrows rising

About to Buy Penny Stocks? Look at These 2 Companies First

These two healthcare stocks are risky, but they have much better chances of success than penny stocks.


dude tossing stacks

Here's Why MacroGenics Jumped 156.6% in the First Half of 2020

Investors remain optimistic that the leading drug candidate can earn marketing approval before the end of the year.


paper airplanes rising

Here's Why SolarEdge Technologies Jumped 46% in the First Half of 2020

After a brief tumble in March, the clean energy company is trading at an all-time high.


businessman rocket

Here's Why Adaptive Biotechnologies Soared 61.7% in the First Half of 2020

Investors expect the company's technology platform to come in handy as the world corrals the coronavirus pandemic.

076 arrow dude getty

Here's Why Incyte Rose 19.1% in the First Half of 2020

Incyte might finally be convincing Wall Street that its pipeline is the real deal.


081 dog head tilted

Here's Why Elanco Animal Health Fell 27.2% in the First Half of 2020

The animal health company's reliance on livestock has proved a risk during an uncertain year. Can a massive acquisition change that?


funky arrows rising

Here's Why Beyond Meat Soared 77.2% in the First Half of 2020

The animal-free protein developer clawed its way back after a disappointing second half of 2019.


stock down erased chalkboard

Here's Why Axsome Therapeutics Fell 20.4% in the First Half of 2020

One of the best investments of 2019 fell on hard times in the first six months of 2020, but it's not as bad as it seems.


stock down angry fist

Here's Why Amarin Tumbled 67.7% in the First Half of 2020

The pharma stock collapsed on the threat of generic competition for a drug that launched in December 2019, but the move may have been a bit of an overreaction.